SCHEMBL5310080

SCHEMBL5310080

O=C(O)c1ccccc1Nc1nc(Cl)ncc1F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 13/20 0.69
MAPK8 P45983 5/20 0.69
CDC7 O00311 2/20 0.69
ALK Q9UM73 1/20 0.69
AURKB Q96GD4 3/20 0.60
CDK19 Q9BWU1 1/20 0.60
JAK2 O60674 2/20 0.53
DAPK3 O43293 1/20 0.47
PAK4 O96013 1/20 0.47
PIM1 P11309 1/20 0.47
CDK2 P24941 1/20 0.47
FLT3 P36888 1/20 0.47
GSK3B P49841 1/20 0.47
CDK9 P50750 1/20 0.47
CDK5 Q00535 1/20 0.47
DYRK1A Q13627 1/20 0.47
MELK Q14680 1/20 0.47
MINK1 Q8N4C8 1/20 0.47
HIPK2 Q9H2X6 1/20 0.47
STK17A Q9UEE5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203456 0.88 MAPK8 (0.61) AURKAMAPK8CDC7ALKAURKB
SCHEMBL3098316 0.86 AURKA (0.66) AURKAMAPK8CDC7ALKPBRM1
SCHEMBL1203432 0.86 ULK1 (0.58) AURKAMAPK8CDC7ALKAURKB
SCHEMBL656020 0.84 AURKA (0.50) AURKAMAPK8CDC7ALKAURKB
SCHEMBL15492024 0.84 AURKA (0.63) AURKAMAPK8CDC7ALKPBRM1
SCHEMBL30039325 0.84 AURKA (0.63) AURKAMAPK8CDC7ALKPBRM1
SCHEMBL15492010 0.84 AURKA (0.63) AURKAMAPK8CDC7ALKPBRM1
SCHEMBL1203547 0.83 AURKA (0.49) AURKAMAPK8CDC7ALKAURKB
SCHEMBL1202883 0.82 CDC25B (0.52) AURKAMAPK8CDC7ALK
SCHEMBL1203944 0.82 AURKA (0.48) AURKAMAPK8CDC7ALKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007048064-A2 AMINO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO claimed
US-9597329-B2 Aurora kinase inhibitors and methods of making and using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC (US) 2017-03-21 US disclosed
US-20170000787-A1 AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2017-01-05 US disclosed
US-9249124-B2 Aurora kinase inhibitors and methods of making and using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2016-02-02 US disclosed
US-20140057913-A1 AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2014-02-27 US disclosed
WO-2007048064-A2 AMINO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed
WO-2007048064-A2 AMINO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057913-A1 AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF AURKC, AURKA, AURKB AURKA 2/4885MAPK8 558/4885CDC7 6/4885
US-20170000787-A1 AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF AURKC, AURKA, AURKB AURKA 2/4885MAPK8 558/4885CDC7 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.